Pulike Biological Engineering Inc
SSE:603566
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pulike Biological Engineering Inc
EPS (Diluted)
Pulike Biological Engineering Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pulike Biological Engineering Inc
SSE:603566
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
¥0
|
CAGR 3-Years
28%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
¥1
|
CAGR 3-Years
25%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
¥2
|
CAGR 3-Years
20%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
EPS (Diluted)
¥2
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
26%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
EPS (Diluted)
¥9
|
CAGR 3-Years
N/A
|
CAGR 5-Years
241%
|
CAGR 10-Years
N/A
|
|
Pulike Biological Engineering Inc
Glance View
Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
See Also
What is Pulike Biological Engineering Inc's EPS (Diluted)?
EPS (Diluted)
0.4
CNY
Based on the financial report for Sep 30, 2025, Pulike Biological Engineering Inc's EPS (Diluted) amounts to 0.4 CNY.
What is Pulike Biological Engineering Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-1%
Over the last year, the EPS (Diluted) growth was 40%. The average annual EPS (Diluted) growth rates for Pulike Biological Engineering Inc have been -3% over the past three years , -5% over the past five years , and -1% over the past ten years .
